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ABSTRACT 
Introductions: Oral Isotretinoin was registered in Nepal almost three 
decades later its first introduction in the USA. It remains the most 
clinically effective medication for acne. Dry eye syndrome is a ‘certain’ 
adverse effect of oral Isotretinoin therapy which can be validated by tear 
film break up time and Schirmer I tests. 
 
Methods: Fifty patients aged above 12 years presenting to Dermatology 
outpatient department of Dhulikhel Hospital with severe nodulocystic 
acne or recalcitrant acne vulgaris not responding to three months of 
systemic antibiotics along with topical agents were included. Tear film 
break up time and Schirmer I tests before, at 45 and 90 days, and one 
month after taking oral Isotretinoin were performed to study association 
of dry eye syndrome due to oral Isotretinoin.  
 
Results: Both eyes of fifty selected patients were sampled. Baseline mean 
tear film break up time of 12.37±4.17sec decreased to 9.69±3.70sec, 
9.09±3.77sec and 10.67±3.50sec at 45 and 90 days and on follow up, 
respectively. Likewise, baseline mean Schirmer I value of 16.68 ± 8.73mm 
decreased to 12.26 ±7.64mm, 11.49 ± 8.07mm and 11.76 ± 8.11mm 
respectively at 45 and 90 days and on follow up. The differences between 
the mean values were analyzed using paired samples T test and all were 
statistically significant except between the mean Schirmer values at 90 
days and on follow up.  
 
Conclusions: Abnormal mean tear break up time at 45 and 90 days in this 
study suggests that dry eye syndrome was caused by oral Isotretinoin 
during acne therapy but tends to revert to normal on cessation. 
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INTRODUCTION  
 
Oral Isotretinoin (13-cis-retinoic acid), was first 
approved in 1982 by the United States Food and 
Drug Administration (FDA) for the treatment of 
severe recalcitrant nodulocystic acne that is 
unresponsive to conventional therapy including 
systemic antibiotics.1,2 Even after three decades, it 
remains the most clinically effective medication for 
acne.3 
 
Abnormal Meibomian gland secretion leading to 
ocular sicca (dry eye) is a ‘certain’ side effect of 
oral Isotretinoin therapy.4 Dry eye syndrome (DES) 
is a clinical condition characterized by deficiency of 
tear production or instability of tear film leading to 
excessive tear evaporation resulting in ocular 
discomfort and visual disturbance as well as 
potential damage to the ocular surface.5 Schirmer 
test and tear film break-up time (BUT) are used to 
grade DES.6 
 
Research regarding Oral Isotretinoin which is 
relatively new to Nepal, is lacking.7 This study 






It was a cross sectional study conducted in the 
Dermatology outpatient department (OPD) of 
Dhulikhel Hospital from April 2013 to April 2014. 
The Institutional Review Committee of Kathmandu 
university School of Medical Sciences, Dhulikhel 
Hospital (IRC-KUSMS) approved the study in 15 
March 2013. Verbal and written consent were 
taken from all the patients (or a parent incase of 
minor) selected for the study after careful 
counseling. 
 
Patients seeking medication for acne, who 
presented to Dermatology OPD of Dhulikhel 
Hospital, from April 2013 till December 2013, were 
evaluated and those with severe nodulocystic acne 
or recalcitrant acne vulgaris (acne not responding 
to three months of systemic antibiotics along with 
topical agents) were chosen.2,8 Among them, only 
patients more than 12 years of age (European 
Directive on Isotretinoin Prescribing) were 
selected.2 Thorough medical history- taking, clinical 
examination and baseline blood investigations 
including complete blood count, erythrocyte 
sedimentation rate, liver function tests, renal 
function tests, random blood sugar and fasting 
lipid profile were done.  
 
In case of females, with additional informed 
consent, urine examination to detect pregnancy 
was also done and was repeated on subsequent 
visits during the study. Female patients found to 
be pregnant or those who were planning to 
become pregnant within four months of the study 
period were strictly excluded from the study as 
Isotretinoin is a Category X drug.9 Oral or systemic 
hormonal contraception were not allowed, to 
avoid interaction with  Isotretinoin.1 Physical 
methods of contraception were encouraged. 
Guidelines for pregnancy monitoring as per the 
textbook2 was not followed due to Nepalese social 
stigma of contraception in the unmarried.  
 
Patients currently or two weeks prior to initiating 
the study, taking systemic or ocular medication 
were excluded from the study. Patients who are or 
had in the past taken oral Isotretinoin were also 
excluded.  Patients found to have ocular disease 
and co-morbid conditions like: atopic dermatitis, 
bronchial asthma, hypertention, diabetes, 
hyperlipidemia, anemia, bleeding disorders, 
hemorrhoids, anal fissures, tuberculosis and 
keloids were excluded from the study. 
All consenting patients fulfilling the above criteria 
were prescribed fixed regimen of Oral soft gel 
capsules of Isotretinoin (0.3 mg/kg daily) after 
dinner for 90 days; oral tablet Prednisolone (0.2 
mg/kg daily; to avoid initial acne flare due to 
Isotretinoin) after lunch and oral tablet 
Pantoprazole (0.7 mg/kg daily; to prevent acid 
peptic disease from Prednisolone) on empty 
stomach for initial 10days; and Petroleum Jelly 
application for chapped lips and dry skin.  
 
Besides examination in the Dermatology OPD, the 
patients were required to undergo eye check-up 
along with BUT and anesthetized Schirmer’s test 
(Schirmer I) in the Ophthalmology OPD by a single 
ophthalmologist prior to starting the therapy 
(baseline); 45 and 90 days of therapy and; 30 days 
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Those patients who developed allergic reaction or 
intolerance to the therapy and; patients requiring 
additional systemic or ocular medication during 
the study were further excluded from the study.  
Initially consenting patients who during the study 
period wanted to withdraw and; non-compliant 
patients who did not turn up for follow-up 
examination on the specified date were excluded 
as well. 
 
In the Ophthalmology OPD, BUT was done prior to 




The test was performed as follows, 
a. Fluorescein 2% was instilled into the lower 
fornix of the right eye. 
b. The patient was asked to blink several 
times. 
c. The tear film was examined with a broad 
beam and a cobalt blue filter.  
d. After an interval of time, black spots or 
lines appeared in the fluorescein stained 
film. 
e. The interval between the last blink and the 
appearance of the first randomly 
distributed dry spot was the BUT and was 
noted. 
f. The above procedure was repeated for the 
left eye. 
 
Schirmer I:  
The test was performed as follows, 
a. A drop of 2% Lignocaine solution was 
instilled into the lower fornix of the right 
and left eye. 
b. Excess tears and instillation were gently 
removed from the fornix with a tissue 
paper. 
c. 5×35 mm strip of Whatman filter papers 
were folded 5mm from one end and 
inserted at the junction of the middle and 
outer third of the lower lids, without 
touching the cornea or lashes. 
d. The patient was asked to keep the eyes 
gently closed. 
e. After 5 minutes, the Whatman papers 
were removed and the amounts of wetting 
from the fold were measured in mm and 
noted. 
 
The DES is a clinical condition characterized by 
deficiency of tear production or instability of tear 
film leading to excessive tear evaporation resulting 
in ocular discomfort and visual disturbance as well 
as potential damage to the ocular surface.5 Ocular 
surface dye staining, BUT, Schirmer test, 
fluorescein clearance test, lacrimal gland function 
and tear osmolarity are clinical tests available for 
the diagnosis of dry eye. However, no single test is 
adequate for establishing the diagnosis. Dry eye 
severity grading scheme was devised by the 
definition and classification subcommittee of the 
International Dry Eye Workshop in 2007. Besides 
ocular symptoms and signs, the scheme takes into 
account BUT and Schirmer I values to grade the 
severity of dry eyes.6 BUT values of less than or 
equal to 10sec and Schirmer I value of less than or 
equal to 10mm are considered abnormal.5,6,10 
 
Considering both eyes of the patients, the number 
of samples considered for statistical analysis was 
double the patient number. 
 
The data were entered in Microsoft Excel 2007 
worksheet and transferred to Statistical Package 
for Social Study (IBM® SPSS® Statistics 20) for 
statistical analysis. Demographics were analyzed 
using descriptive statistics whereas Paired Samples 
T test was used to compare the means. Pearson chi 
square value at 0.05 level of confidence was 






Fifty cases were included in the study. The mean 
age of the study group was 23.70 ± 4.381 years. 
The youngest patient was 16 years and eldest 33 
years old. Among 50 patients, 30 (60%) were male 
and 20 (40%) female. Among the 30 male patients, 
13 (43%) had severe nodulocystic acne and 17 
(57%) had recalcitrant acne vulgaris, whereas 
among the 20 female patients, eight (40%) had 
severe nodulocystic acne and 12 (60%) had 
recalcitrant acne vulgaris. The mean weight of the 
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Table 1. Tear break up time (BUT) in patients (n=50) receiving 
Isotretinoin for acne  
Tear BUT (seconds) Mean ± SD p-value 
Baseline 12.37±4.17  
At 45 days 9.69±3.70 0.000 
At 90 days 9.09±3.77 0.004 
Follow up  10.67±3.50 0.000 
 
Table 2. Schirmer I test in patients (n=50) receiving 
Isotretinoin for acne  
Schirmer I test (mm) Mean ± SD p-value 
Baseline 16.68 ± 8.73  
At 45 days  12.26 ±7.64 0.000 
At 90 days  11.49 ± 8.07 0.045 
Follow up 11.76 ± 8.11 0.427 
 
 Table 3. BUT and Schirmer I at baseline and on follow up in 
patients (n=50) receiving Isotretinoin for acne  
n=50 Baseline  Follow up p-value 












In this study, the mean baseline value of BUT 
decreased significantly at 45 days and 
subsequently at 90 days but increased significantly 
thereafter on follow up. This is in accordance with 
the study done by Karalezli A et al11 in which there 
were statistically significant differences in BUT 
values at baseline with that during, at the end and 
the follow up of oral Isotretinoin therapy. 
However, there is difference in the statistical 
analysis between the two studies. The current 
study compares the means at baseline with 45 
days; 45 days with 90 days and 90days with follow 
up after 30 days, to elucidate the progression of 
decrease.  When means at baseline and follow up 
were compared, the reduction in BUT was still 
statistically significant signifying that: even when 
BUT tends to increase after cessation of oral 
Isotretinoin, it does not reach the baseline value 
after one month. Cumurcu et al12 also found dose 
dependent decrease in BUT values at 45 and 90 
days of treatment with systemic isotretinoin. 
 
There was statistically significant decrease in the 
mean Schirmer I value at 45 days and 90 days but 
no statistically significant decrease on follow up. 
However, there was marked statistically significant 
decrease on follow up compared with the baseline. 
Similar results were seen in the study by Karalezli A 
et al11 in which Schirmer I values decreased 
significantly at 30 and 120 days of treatment with 
0.8 mg/kg Isotretinoin compared with the baseline. 
Cumurcu et al12 found that the decrease in 
Schirmer I values did not differ with dose of 
Isotretinoin. Mathers et al13 and Bozkurt et al14 who 
performed Schirmir II test on patients taking 
isotretinoin, did not find any statistically significant 
change before, during and after treatment. This is 
because Schirmer II indicates the volume of tears 
produced by lacrimal glands after irritation of the 
ocular surface whereas Schirmer I represents the 
basal tear secretion.5,6  
 
Reports on the effect of isotretinoin therapy on 
production of the aqueous component of tears are 
not conclusive. Studies by Rismondo and 
colleagues demonstrate presence of Isotretinoin in 
lacrimal gland secretion of rabbits and humans. 
However, they concluded that it is not toxic to the 
lacrimal gland per se but its presence in the tear 
fluid may be related in part to its adverse ocular 
side effects.15,16 The decrease in mean Schirmer I 
value during oral Isotretinoin therapy in this study 
and in the study by Karalezli A et al11 could be due 
to the alteration of basal tear secretion by the 
presence of Isotretinoin and its metabolites in the 
tear film. 
 
Though the mean values of Schirmer I decreased 
significantly in this study, it was never 10mm or 
less than that to label it as abnormal. On the other 
hand, mean BUT values at 45days and 90days were 
less than 10sec and were considered abnormal. 
DES is a clinical diagnosis. As clinical ocular findings 
were not taken into account, this study cannot 
conclude that oral Isotretinoin causes DES. 
However, with the findings of: 1) progressive 
decrease in mean BUT and Schirmer I values during 
oral isotretinoin therapy; 2) abnormal mean BUT 
while on treatment and; 3) slow increase in mean 
BUT and Schirmer I values after one month of its 
discontinuation; this study infers that oral 
Isotretinoin therapy for acne can cause DES. Larger 
studies considering the ocular clinical features as 
well as other diagnostic tests are required to 
further authenticate this statement. In day to day 
practice, artificial tears can be prophylactically 
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Besides DES, oral isotretinoin can commonly cause 
conjunctivitis, hordeolum, chalazion, blepharitis, 
eye pain and more rarely, corneal opacities, 
decreased dark adaptation, decreased tolerance to 
contact lens, decreased vision etc.4,23 Thus, 
patients undergoing oral isotretinoin therapy 
should be individualized and referred to an 




Abnormal findings of BUT during this study concurs 
that DES can be induced by Isotretinoin. In this 
study, abnormal BUT values caused by Isotretinoin 
was not severe and tended to revert to baseline 
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